Contract Development Services

Lonza Announces Additional Investments in Global Particle Engineering Services

July 06, 2020

Lonza is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.

Demand for Custom Dosage Forms Fuels Innovation

July 02, 2020

Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.

Contractors Balance Increased Demand During COVID-19

July 02, 2020

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment

May 04, 2020

FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.

How Fast Is Too Fast?

May 02, 2020

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

Catalent to Manufacture J&J’s Lead COVID-19 Vaccine Candidate

April 30, 2020

Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Delivering the Goods

April 02, 2020

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Keeping Toxicity to a Minimum

March 02, 2020

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.

Fast vs. Formulated?

March 02, 2020

Can investing in early formulation studies drive a new therapy successfully across the commercialization finish line?

ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement

February 28, 2020

Pharmaceutical Technology's In the Lab eNewsletter

Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.